Amendments to the Claims:

1-29. (canceled)

30. (currently amended) A solid or solid-containing pharmaceutical formulation comprising a crystalline form of risperidone with a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable excipient, wherein the crystalline form of risperidone is characterized by x-ray powder diffraction peaks at 14.0±0.2 and 21.7±0.2 degrees two-theta.

31. (canceled)

32. (currently amended) The solid or solid-containing pharmaceutical formulation of claim 30, wherein the crystalline form of risperidone is further characterized by x-ray powder diffraction peaks at 10.8±0.2, 11.9±0.2, 12.6±0.2, 14.0±0.2, 17.5±0.2, 18.3±0.2, 19.9±0.2, 21.0±0.2, and 21.7±0.2 degrees two-theta.

33. (currently amended) A solid or solid-containing pharmaceutical formulation comprising a crystalline form of risperidone with a pharmaceutically acceptable carrier and/or pharmaceutically acceptable excipient, wherein the crystalline form of risperidone is characterized by a x-ray powder diffraction pattern substantially as depicted in Figure 2.

34. (currently amended) The solid or solid-containing pharmaceutical formulation of claim 30, 32 or 33 wherein the solid or solid-containing pharmaceutical formulation is in a dosage form suitable for oral administration or intravenous administration.

35. (currently amended) The solid or solid-containing pharmaceutical formulation of claim 34 wherein the dosage form is selected from the group consisting of a tablet, compressed pill, coated pill, dragee, sachet, hard capsule, gelatin capsule, sub-lingual tablet, and suspension, wherein the crystalline form of risperidone in the suspension is solid.

36. (currently amended) A method for treating psychosis in a patient comprising administering to the patient the solid or solid-containing pharmaceutical formulation of claim 30, 32 or 33.

37. (currently amended) The method of claim 36, wherein the crystalline form of risperidone in the solid or solid-containing pharmaceutical formulation is administered at a daily dosage of about 4 to about 16 mg per day.

38. (currently amended) The method of claim 36, wherein the crystalline form of risperidone in the solid or solid-containing pharmaceutical formulation is administered at a daily dosage of about 4 to about 8 mg per day.

39. (currently amended) A solid or solid-containing pharmaceutical dosage formulation comprising an active ingredient and at least one component selected from the group consisting of pharmaceutical acceptable carriers and pharmaceutical acceptable excipients, wherein the active ingredient consists essentially of a crystalline form of risperidone characterized by x-ray powder diffraction peaks at 14.0±0.2 and 21.7±0.2 degrees two-theta.

40. (currently amended) The solid or solid-containing pharmaceutical dosage formulation of claim 39 wherein the dosage formulation is in a form selected from the group consisting of a tablet, compressed pill, coated pill, dragee, sachet, hard

capsule, gelatin capsule, sub-lingual tablet and suspension, wherein the crystalline form of risperidone in the suspension is solid.

41. (currently amended) A method of treating psychosis in a patient comprising administering to the patient the solid or solid-containing pharmaceutical dosage formulation of claim 39 or 40, wherein the crystalline form of risperidone in the pharmaceutical dosage formulation is administered at a daily dosage of about 4 to about 16 mg per day.

42. (currently amended) A solid or solid-containing pharmaceutical formulation comprising a crystalline form of risperidone with a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable excipient, wherein the crystalline form of risperidone is characterized by x-ray powder diffraction peaks at 14.0±0.2 and 21.3±0.2 degrees two-theta.

43. (currently amended) The solid or solid-containing pharmaceutical formulation of claim 42, wherein the crystalline form of risperidone is further characterized by x-ray powder diffraction peaks at 10.6±0.2, 11.4±0.2, 16.4±0.2, 18.9±0.2, 19.9±0.2, 22.5±0.2, 23.3±0.2, 25.4±0.2, 27.6±0.2 and 29.0±0.2 degrees two-theta.

44. (currently amended) A solid or solid-containing pharmaceutical formulation comprising a crystalline form of risperidone with a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable excipient, wherein the crystalline form of risperidone is characterized by a x-ray powder diffraction pattern substantially as depicted in Figure 1.

45. (currently amended) The solid or solid-containing pharmaceutical formulation of claim 42, 43 or 44, wherein the pharmaceutical formulation is in a dosage form suitable for oral administration or intravenous administration.

46. (currently amended) The solid or solid-containing pharmaceutical formulation of claim 45, wherein the dosage form is selected from the group consisting of a tablet, compressed pill, coated pill, dragee, sachet, hard capsule, gelatin capsule, sub-lingual tablet and suspension, wherein the crystalline form of risperidone in the suspension is solid.

47. (currently amended) A method for treating psychosis in a patient, comprising administering to the patient the solid or solid-containing pharmaceutical formulation of claim 42, 43 or 44.

48. (currently amended) The method of claim 47, wherein the crystalline form of risperidone in the solid or solid-containing pharmaceutical formulation is administered at a dose of about 4 to about 16 mg per day.

49. (currently amended) The method of claim 48, wherein the crystalline form of risperidone in the solid or solid-containing pharmaceutical formulation is administered at a dose of about 4 to about 8 mg per day.

50. (currently amended) A solid or solid-containing pharmaceutical dosage formulation comprising an active ingredient and at least one component selected from the group consisting of pharmaceutical acceptable carriers and pharmaceutical acceptable excipients, wherein the active ingredient consists essentially of a crystalline form of risperidone characterized by x-ray powder diffraction peaks at 14.0±0.2 and 21.3±0.2 degrees two-theta.

51. (currently amended) The solid or solid-containing pharmaceutical dosage formulation of claim 50, wherein the dosage formulation is in a form selected from the group consisting of a tablet, coated pill, compressed pill, dragee, sachet, hard capsule, gelatin capsule, sub-lingual tablet and suspension, wherein the crystalline form of risperidone in the suspension is solid.

52. (currently amended) A method of treating psychosis in a patient, comprising administering to the patient the solid or solid-containing pharmaceutical dosage formulation of claim 50, wherein the crystalline form of risperidone in the pharmaceutical dosage formulation is administered at a dose of about 4 to about 16 mg per day.